Document Detail


Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: a pilot phase II study.
MedLine Citation:
PMID:  23225458     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Bevacizumab is a monoclonal antibody that prevents angiogenesis by inhibiting vascular endothelial growth factor (VEGF) activity. Clinically, it has been used to treat a diverse range of cancer types. In this pilot phase II study, we investigated the efficacy and safety profiles of bevacizumab in combination with docetaxel plus cisplatin for patients with advanced HER2-negative metastatic breast cancer.
PATIENTS AND METHODS: Between 2005 and 2008, 20 patients with advanced breast cancer were recruited from the Taipei Medical University Hospital. Bevacizumab was administered every two weeks in a 12-cycle treatment with docetaxel plus cisplatin. The primary end-point for this study was the overall response rate. The secondary end-points were progression-free survival and the safety profiles of the combined therapy.
RESULTS: The average number of treatment cycles was 10.5 with a response rate of 80%. Neutropenia and neuropathy were the most commonly observed adverse events. Seven patients achieved complete remission and nine patients achieved partial remission. For the overall patient group in this study, the median time-to-progression and overall survival were 28.0 weeks and 52 weeks, respectively. The median time-to-progression and overall survival for the 10 patients that completed all 12 cycles of treatment were 64.0 weeks and 80 weeks, respectively. In one patient, a very rapid reduction in the level of breast cancer lung metastases was observed one week post-treatment.
CONCLUSION: Based on this pilot study, bevacizumab in combination with docetaxel and cisplatin is likely to be an effective treatment option for metastatic breast cancer that warrants further study.
Authors:
Cheng-Jeng Tai; Ching-Shyang Chen; Chin-Sheng Hung; Li-Jen Kuo; Po-Li Wei; Jeng-Feng Chiou; Chung-Huei Hsu; Hung-Yi Chiou; Chih-Hsiung Wu
Related Documents :
24616308 - Circulating tumor cell counts are prognostic of overall survival in swog s0421: a phase...
24787968 - Response to subsequent docetaxel in a patient cohort with metastatic castration-resista...
18299238 - Treatment outcomes in squamous cell carcinoma of the maxillary alveolus and palate: a p...
7425238 - What is the preferred initial method of treatment for squamous carcinoma of the tongue?
2439668 - Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous sy...
9439368 - Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin c.
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2013-05-02     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5501-6     Citation Subset:  IM    
Affiliation:
Superintendent, Superintendent Office, Taipei Medical University Shuang-Ho Hospital, No.291, Jhongjheng Rd, Jhonghe City, Taipei County 235, Taiwan, ROC. cjtai@tmu.edu.tw
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Breast Neoplasms / drug therapy*
Cisplatin / administration & dosage,  adverse effects
Disease-Free Survival
Female
Humans
Middle Aged
Pilot Projects
Taxoids / administration & dosage,  adverse effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Taxoids; 15663-27-1/Cisplatin; 15H5577CQD/docetaxel; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 1...
Next Document:  Expression Analysis of iPS Cell - Inductive Genes in Esophageal Squamous Cell Carcinoma by Tissue Mi...